[heading title_size=”title-size-x-large” subtitle=”Boston Marriot Long Wharf | August 3-5, 2018″]SCIENTIFIC PROGRAM[/heading]
[heading title_size=”title-size-medium” custom_attribs=”undrln” subtitle=”Event Schedule Subject to Change”]Program at a Glance[/heading]
1:30 PM
WELCOME AND INTRODUCTION
1:30 PM – 6:00 PM
SESSION I: LEADERS OF ACADEMIA AND INDUSTRY ON ACCELERATING INNOVATION AND ADOPTION OF PRECISION ONCOLOGY FOR PROSTATE CANCER: Challenges & Solutions
6:30 PM
WELCOME DINNER RECEPTION, EXHIBIT TOURS, AND POSTER SESSION
FRIDAY, OCTOBER 4, 2019
8:00 AM – 11:30 AM
SESSION II. PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: PRECISION SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
11:30 AM – 1:00 PM
LUNCH BREAK
1:00 PM – 6:30 PM
SESSION III. DIAGNOSTIC ASSESSMENT OF MEN WITH PROVEN LOCALIZED PROSTATE CANCER: Prediction of Progression, Staging, and Patient Selection for Treatment
7:30 PM – 9:30 PM
DINNER RECEPTION, EXHIBIT TOURS, AND POSTER SESSION
SATURDAY, OCTOBER 5, 2019
8:00 AM – 9:30 AM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF FOCAL TREATMENT
9:50 AM – 12:30 PM
SESSION V: PRECISION ONCOLOGY FOR RECURRENT AND ADVANCED PROSTATE CANCER
12:30 PM – 2 PM
LUNCH
2:00 PM – 5:00 PM
SESSION V. SUMMARY PANEL DISCUSSION OF SUMMIT HIGHLIGHTS – Most Promising Clinical and Research Trends in Precision Screening, Diagnosis and Treatment
5:00 PM
ADJOURN PUBLIC PROGRAM
1:30 PM
WELCOME AND INTRODUCTION:
Faina Shtern, MD, President and CEO, AdMeTech Foundation
1:40 PM
SESSION I: LEADERS OF ACADEMIA AND INDUSTRY ON ACCELERATING INNOVATION AND ADOPTION OF PRECISION ONCOLOGY FOR PROSTATE CANCER: Challenges & Solutions
Moderators
Grannum Sant, MD, FRCS, FACS, Professor and Former Chair of Urology, Tufts University School of Medicine; Former Head, Oncology/Urology Medical Affairs, Sanofi, and Rare Genetic Diseases, Genzyme
Howard Soule, PhD, Executive Vice President and Chief Science Officer, Prostate Cancer Foundation
Stephen Zappala, MD, Assistant Clinical Professor of Urology, Tufts University School of Medicine
1:45 PM
Liquid Biomarkers: Validation and Implementation
Kelvin Moses, MD, PhD, Assistant Professor of Urology and Chief of Urology, Nashville General Hospital, Ingram Cancer Center, Vanderbilt University; and Member, National Comprehensive Cancer Network (NCCN)’s Prostate Cancer Early Detection Panel
2:00 PM
Industry Leadership Panel (Speakers TBC)
2:30 PM
Coffee Break
2:55 PM
Genetic Cancer Profiling: Clinical Utility and State of Adoption
Mohummad Minhaj Siddiqui, MD, Associate Professor of Surgery, Director of Urologic Oncology and Robotic Surgery, University of Maryland Medical System, and Chief of Urology, Baltimore VA Medical Center
3:10 PM
Industry Leadership Panel (Speakers TBC)
3:40 PM
Diagnostic Imaging
Baris Turkbey, MD, Staff Physician, Molecular Imaging, Center for Cancer Research, National Cancer Institute, National Institutes of Health
3:55 PM
Industry Leadership Panel (Speakers TBC)
4:15 PM
Precision Treatment
Adam Kibel, MD, Professor and Chief of Urology, Brigham and Women’s Hospital, Dana Farber Cancer Institute, Harvard Medical School; and Member, National Comprehensive Cancer Network (NCCN)’s Prostate Cancer Early Detection Panel
Michael Zelefsky, MD, Vice Chair, Department of Radiation Oncology, Clinical Research; and Chief, Brachytherapy Service, Memorial Sloan Kettering Cancer Center
David Nanus, MD, Mark W. Pasmantier Professor and Chief, Hematology and Oncology, New York-Presbyterian, and Director of Genitourinary Oncology, Weill Cornell Medicine
4:45 AM
Industry Leadership Panel (Speakers TBC)
5:15-6:00 PM
Panel Discussion: Moderators and Speakers
6:30 PM
Welcome Dinner Reception, Exhibit Tours and Poster Session
8:00 AM
SESSION II. PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: PRECISION SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators
Richard Babayan, MD, Professor and Chairman, Department of Urology, Boston University School of Medicine; and Chief of Urology, Boston Medical Center
Masoom Haider, MD, Professor of Radiology and Vice Chair, Radiomics and Quantitative Imaging, University of Toronto, Canada
8:10 AM
State of the Art in “Smart” Prostate Cancer Screening: Defining the Need for Precision Diagnostics
Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden
8:25 AM
Q & A
8:30 AM
Current and Emerging Fluid-Based Molecular Diagnostics for Improving Risk Assessment and Selection of Patients for Biopsy
Novel Liquid Diagnostics
David Crawford, MD, E. David Crawford Distinguished Endowed Chair in Urology, University of Colorado, Denver (TBC)
8:45 AM
Q & A
8:50 AM
Current and Emerging Imaging Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
Current State of the Art and Future Directions in Ultrasound Imaging
Ethan Halpern, MD, Professor and Vice Chair for Research, Department of Radiology; and Co-Director, Prostate Diagnostic Center, Jefferson University Hospital
9:05 AM
Real-time High-Resolution Micro-Ultrasound:
Sangeet Ghai, MD, Associate Professor, Department of Medical Imaging, University of Toronto, Canada
9:20 AM
Q & A
9:25 AM
Multi-Parametric (mp) Magnetic Resonance Imaging, PI-RADS Standardization and Targeted Biopsy
Jeffrey Weinreb, MD, Professor and Vice Chair for Strategic Planning and Innovation, Department of Diagnostic Radiology and Biomedical Imaging,Yale School of Medicine
9:40 AM
Q & A
9:45 AM
Coffee Break
10:15 AM
NCCN Guidelines for Early Detection of Prostate Cancer: Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel
10:30 AM
Q & A
10:35 AM
Integrated Multi-Modality Diagnostic Evaluation: Sanoj Punnen, MD, Assistant Professor of Surgery, University of Miami Miller School of Medicine
10:50 AM
Q & A
10:55 AM
Panel Discussion: Emerging Best Practices and Research Priorities
Moderators and Speakers
11:30 AM
Lunch Break
1:00 PM
SESSION III. DIAGNOSTIC ASSESSMENT OF MEN WITH PROVEN LOCALIZED PROSTATE CANCER: Prediction of Progression, Staging, and Patient Selection for Treatment
Moderators
Jelle Barentsz, MD, PhD, Chair and Professor of Radiology Prostate MR Center of Excellence, Nijmegen Medical Center, Radboud University, The Netherlands
Neal Shore, MD, Director, Carolina Urologic Research Center, Atlantic Urology Clinics (TBC)
1:05 PM
Keynote Address: Genetic Cancer Profiling:
Eric Klein, MD, Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic
1:20 PM
Q & A
1:25 PM
In Vivo Imaging
Current Clinical Utility of mpMRI and Multi-Modality Diagnostics
Jelle Barentsz, MD, PhD
1:40 PM
Q&A
1:45 PM
Molecular Imaging
Urology Perspective: Ashley Ross, MD, PhD, Urology Specialists, Texas Oncology; Associate Chair, US Oncology GU Research Committee; and Executive Medical Director, Mary Crowley Cancer Research Center
1:55 PM
Radiology Perspective on Non-Invasive Imaging: Daniel Margolis, MD, Associate Professor of Radiology and Director, Prostate MRI and Abdominal Imaging, Weill Cornell Medicine
2:10 PM
Intra-Operative Imaging: Wolfgang Weber, MD, Professor and Chair, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
2:25 PM
Q & A
2:30 PM
Radiomics and Machine Learning: Masoom Haider, MD
2:45 PM
Coffee Break
3:15 PM
Tissue-Based Pathologic Assessment, Genomics and Phenotypic Biomarkers
Anatomic Pathology: Thomas Wheeler, MD, Chairman and Professor of Pathology, Baylor College of Medicine
3:30 PM
Molecular Pathology: Angelo DeMarzo, MD, PhD, Associate Professor of Pathology, Urology, Oncology, Johns Hopkins University School of Medicine (TBC)
3:45 PM
Q & A
3:50 PM
Phenotypic Biomarkers: David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York; and Medical Director for Associated Medical Professionals
4:05 PM
Q & A
4:10 PM
Emerging Trends in Prostate Cancer Treatment:
Mack Roach, Professor of Radiation Oncology and Urology, UCSF
4:25 PM
Precision Diagnosis and its Emerging Impact on Precision Radiation Treatment
Alan Pollack, MD, PhD, Professor and Chair, Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System
4:40 PM
Q & A
4:45 PM
Radiogenomics: Emerging and Future Impact on Treatment Selection and Monitoring
Active Surveillance – Mohummad Minhaj Siddiqui, MD, Associate Professor of Surgery, Director of Urologic Oncology and Robotic Surgery, University of Maryland Medical System, and Chief of Urology, Baltimore VA Medical Center
5:00 PM
Focal Treatment – Fiona Fennessy, MD, PhD, Cancer Imaging Program Fellowship Director, Dana Farber Cancer Institute; and Associate Professor of Radiology, Harvard Medical School
5:15 PM
Precision Whole Gland Treatment
Radiation Oncology Perspective: Ashesh B. Jani, MD, MSEE, Professor, Department of Radiation Oncology, Emory University
Urology Perspective – Adam Feldman, MD, MPH, Assistant Professor of Surgery and Director of Combined Harvard Urology Oncology Fellowship, Massachusetts General Hospital, Harvard Medical School
5:45 PM
Q & A
7:30-9:30 PM
Dinner Reception, Exhibit Tours and Poster Session
5:50 PM-6:30 PM
Panel on Diagnostic Evaluation of Men with Proven Localized Prostate Cancer and its Impact on Treatment Design and Monitoring: Speakers, Moderators and Panel Members –
Multi-Parametric Nomograms: Amita Dave, PhD, Associate Attending Physicist and Deputy Service Chief for Predictive Informatics, Memorial Sloan Kettering Cancer Center
Addressing Tumor Heterogeneity: Radka Stoyanova, Ph.D, Professor and Director, Imaging and Biomarkers, Research Department of Radiation Oncology; and Associate Member, Sylvester Comprehensive Cancer Center, Miller School of Medicine University of Miami
Precision Radiation Treatment: Danny Y Song, Co-Director, Prostate Cancer Multidisciplinary Clinic and Associate Professor of Radiation Oncology and Molecular Radiation Sciences, Urology and Oncology, Johns Hopkins University School of Medicine
8:00 AM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF FOCAL TREATMENT
Moderators
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
Jason Efstathiou, MD, D. Phil., Director, Genitourinary Service, Department of Radiation Oncology; and Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic and Associate Professor of Radiation Oncology, Massachusetts General hospital, Harvard Medical School
Sadhna Verma, MD, Professor of Radiology, University of Cincinnati College of Medicine
8:05 AM
Multimodality Precision Diagnostics for Target Definition
8:05 AM
MR/Ultrasound Fusion: Jurgen Futterer, MD, PhD, Interventional Radiologist, Nijmegen Medical Center and Professor, University of Twente, The Netherlands
8:20 AM
Multi-Modality Imaging and Radiogenomics: John Feller, MD, Founder, Desert Medical Imaging
8:35 AM
Q & A
8:40 AM
Overview of Patient Selection, Monitoring and Outcomes
Radiology Perspective: Aytekin Oto, MD, MBA, Professor of Radiology and Section Chief, Abdominal Imaging; Chief of Body MRI; and Interim Vice Chair for Business Development, Department of Radiology, University of Chicago
8:55 AM
Urology Perspective: Gerald L. Andriole, MD, Robert Royce Distinguished Professor, Chief of Urologic Surgery, and Vice-Chair, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center; and Member, National Comprehensive Cancer Network (NCCN)’s Prostate Cancer Early Detection Panel
9:10 AM
Panel Discussion: Moderators, Speakers
9:30 AM
Coffee Break
9:30 AM
SESSION V: PRECISION ONCOLOGY FOR RECURRENT AND ADVANCED PROSTATE CANCER
Moderators
David Nanus, MD, Mark W. Pasmantier Professor and Chief, Hematology and Oncology, New York-Presbyterian, and Director of Genitourinary Oncology, Weill Cornell Medicine
Alan Pollack, MD
9:50 AM
Overview of Precision Oncology for Advanced Prostate Cancer, Including Oligometastatic Disease – Christopher Sweeney, MBBS, Clinical Director, Lank Center for Genitourinary Oncology and Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School
10:05 AM
Q&A
10:10 AM
Liquid Biopsy
David Nanus, MD, Mark W. Pasmantier Professor and Chief, Hematology and Oncology, New York-Presbyterian, and Director of Genitourinary Oncology, Weill Cornell Medicine
10:25 AM
Q & A
10:30 AM
Genomic Testing, including Germline Mutations: Peter Nelson, MD, Endowed Chair for Prostate Cancer Research, Fred Hutchinson Cancer Research Center; Professor of Medical Oncology, University of Washington Medicine; and Genitourinary Oncology Clinical Research Director, Seattle Cancer Care Alliance (TBC)
10:45 AM
Q & A
11:00 AM
Molecular and Multi-Modality Imaging
Prostate Specific PET Imaging Overview: Next Step in Defining Clinical Utility: Christopher Sweeney, MD
11:15 AM
Q & A
11:20 AM
Impact of 18F-fluciclovine on Management of Patients with Suspected Recurrence: Gerald L. Andriole, MD
11:35 AM
Q&A
11:40 AM
Clinical Experience with PSMA PET:
Steven Rowe, MD, PhD, Assistant Professor of Radiology, Johns Hopkins University School of Medicine
Thomas Hope, MD, Assistant Professor in Residence in the Abdominal Imaging and Nuclear Medicine, Department of Radiology, University of California, San Francisco (TBC)
12:10 PM
Theranostics of Prostate Cancer: Wolfgang Weber, MD
12:15 PM
Q & A
12:30 PM – 2:00 PM
Lunch
2:00 PM – 5:00 PM
SESSION V. SUMMARY PANEL DISCUSSION OF SUMMIT HIGHLIGHTS –
Most Promising Clinical and Research Trends in Precision Screening, Diagnosis and Treatment
Session Leaders: Mark Buzza, PhD, MBA, Director, Global Biomedical Research Programs, Movember Foundation, Australia and Faina Shtern, MD
Moderators and Speakers
5:00 PM
ADJOURN